Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling  by Massoumi, Ramin et al.
Cyld Inhibits Tumor Cell
Proliferation by Blocking
Bcl-3-Dependent NF-kB Signaling
Ramin Massoumi,1 Katarzyna Chmielarska,1 Katharina Hennecke,2 Alexander Pfeifer,2 and Reinhard Fa¨ssler1,*
1Department of Molecular Medicine, Max Planck Institute of Biochemistry, D-82152 Martinsried, Germany
2Molecular Pharmacology, Department of Pharmacy, Ludwig-Maximilians-Universita¨t Mu¨nchen, D-81377 Munich, Germany
*Contact: faessler@biochem.mpg.de
DOI 10.1016/j.cell.2006.03.041SUMMARY
Mutations in the CYLD gene cause tumors of
hair-follicle keratinocytes. The CYLD gene en-
codes a deubiquitinase that removes lysine
63-linked ubiquitin chains from TRAF2 and in-
hibits p65/p50 NF-kB activation. Here we show
that mice lacking Cyld are highly susceptible
to chemically induced skin tumors. Cyld/ tu-
mors and keratinocytes treated with 12-O-tetra-
decanoylphorbol-13 acetate (TPA) or UV light
are hyperproliferative and have elevated cyclin
D1 levels. The cyclin D1 elevation is caused
not by increased p65/p50 action but rather by
increased nuclear activity of Bcl-3-associated
NF-kB p50 and p52. In Cyld+/+ keratinocytes,
TPA or UV light triggers the translocation of
Cyld from the cytoplasm to the perinuclear re-
gion, where Cyld binds and deubiquitinates
Bcl-3, thereby preventing nuclear accumulation
of Bcl-3 and p50/Bcl-3- or p52/Bcl-3-dependent
proliferation. These data indicate that, depend-
ing on the external signals, Cyld can negatively
regulate different NF-kB pathways; inactivation
of TRAF2 controls survival and inflammation,
while inhibition of Bcl-3 controls proliferation
and tumor growth.
INTRODUCTION
Patients with familial cylindromatosis develop multiple,
benign tumors of skin appendages (called cylindromas)
predominantly in their scalp, neck, and face region (van
Balkom and Hennekam, 1994). The cause of cylindroma
development is the loss of both CYLD alleles (Bignell
et al., 2000). CYLD encodes a 107 kDa polypeptide that
is ubiquitously expressed and contains a deubiquitinating
domain (UCH) at the C terminus, which removes lysine 63
(K63) linked polyubiquitin chains from TNF receptor bound
TRAF2 (Trompouki et al., 2003; Brummelkamp et al.,2003; Kovalenko et al., 2003; Regamey et al., 2003). Poly-
ubiquitin chains that are linked through K63 usually serve
as docking sites for other proteins, while chains linked
through K48 of ubiquitin target proteins to the proteasome
for degradation (Pickart 2001; Weissman 2001). The re-
moval of the K63-linked polyubiquitin chain from TRAF2
by CYLD leads to the inhibition of the IkB kinase (IKK)
complex, stabilization of the NF-kB inhibitor IkB-a, and
retention of the classic NF-kB heterodimer p65/p50 in
the cytoplasm. Hence, it was postulated that mutations
in the CYLD gene cause hyperactivation of p65/p50 NF-
kB, leading to tumor cell survival and the formation of cy-
lindromas (Trompouki et al., 2003; Brummelkamp et al.,
2003; Kovalenko et al., 2003). In contrast to this hypothe-
sis, however, it has been shown that transgenic overex-
pression of constitutively nuclear p50 and p65 NF-kB in
keratinocytes of mice results in epidermal hypoplasia
and growth inhibition rather than epidermal hyperplasia
(Seitz et al., 1998). Thus, it is not fully understood how
loss of CYLD induces the formation of cylindromas and
whether increased NF-kB signaling plays a role in skin
tumor formation.
The NF-kB family consists of five members called p65
(RelA), RelB, c-Rel, p50/p105 (NF-kB1), and p52/p100
(NF-kB2). They regulate a broad spectrum of physiological
and pathophysiological processes such as inflammation,
immune response, cell survival, and cell proliferation
(Ghosh and Karin, 2002). While p65 (RelA), RelB, and
c-Rel are synthesized as mature proteins associated
with inhibitory factor IkB protein, p50 and p52 are first syn-
thesized as large precursors termed p105 and p100, re-
spectively. A variety of signals can release cytoplasmic
retention and trigger the nuclear translocation of NF-kB
through induced degradation of either IkB proteins (ca-
nonical NF-kB pathway) or IkB-homologous regions in
the C terminus of p105 and p100 (alternative NF-kB path-
way). RelB, c-Rel, and p65 (RelA) contain a DNA binding
domain (called Rel homology domain) through which
they interact with NF-kB binding sites of target genes
and a transactivation domain through which they activate
transcription (Ghosh and Karin, 2002; Israel, 2000). In con-
trast, p50 and p52 have only a DNA binding domain and
lack a transactivation domain. Therefore, p50 and p52Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc. 665
are only able to promote gene transcription if they either
form a heterodimer with p65 (RelA), RelB, or c-Rel or recruit
the coactivator Bcl-3, which contains a transactivation
domain that switches the transcriptional properties of
NF-kB p50 or p52 homodimers from a repressive to an ac-
tivating state (Watanabe et al., 1997; Fujita et al., 1993).
Bcl-3 was originally identified in a subgroup of B cell leu-
kemias that carry a translocation of the immunoglobulin
heavy chain (IgH) promoter adjacent to the Bcl-3 coding
region (McKeithan, et al., 1990). Subsequently, it was dem-
onstrated that Bcl-3 associates with the NF-kB p50 or p52
subunits and strongly enhances cell proliferation and on-
cogenesis through activation of the cyclin D1 promoter
(Westerheide et al., 2001, Rocha et al., 2003). In B and
T cells, as well as in transiently transfected cells, Bcl-3
exhibited predominantly nuclear localization (Nishikori
et al., 2003; Zhang et al., 1994; Nolan et al., 1993; Bours
et al., 1993), while in several other cell types such as eryth-
roblasts or hepatocytes, Bcl-3 resides in the cytoplasm
and requires activation prior to nuclear translocation
(Zhang et al., 1998; Brasier et al., 2001). The signals that
activate Bcl-3 and recruit Bcl-3 to the NF-kB p50 and
p52 subunits in the nucleus are not known.
Here we show that mice lacking Cyld are prone to
chemically induced skin tumors. Our data indicate that
Cyld inhibits tumor formation and keratinocyte prolifera-
tion by removing K63-linked polyubiquitin chains from
Bcl-3, which results in retention of Bcl-3 in the cytoplasm.
In Cyld-deficient keratinocytes, Bcl-3 accumulates in the
nucleus, activates the NF-kB subunits p50 and p52, and
induces the transcription of NF-kB target genes such as
the cyclin D1 gene.
RESULTS
Cyld/ Mice Are Highly Sensitive to Skin
Tumor Development
To explore the function of Cyld in vivo, we generated Cyld-
deficient mice by inserting a lacZ reporter gene into the
ATG-encoding exon 4 (see Figure S1 in the Supplemental
Data available with this article online). We confirmed the
absence of Cyld mRNA and protein in cells and tissues
from Cyld/ mice by Western blot and RT-PCR analyses
(Figure 1A and Figure S1). Cyld/ mice had no apparent
phenotype, even in the skin epithelium, where Cyld is
prominently expressed (Figures 1A and 1B). Moreover,
Cyld/ mice displayed normal numbers of proliferating
keratinocytes in the basal layers of the epidermis and in
the hair matrix (data not shown). Furthermore, they were
fertile, had a normal life span, and did not spontaneously
develop tumors.
To assess the tumor suppressor function of Cyld in vivo,
we induced skin tumors by treating Cyld/ mice and lit-
termate controls with a single initiation dose of 7,12-dime-
thylbenz(a)anthracene (DMBA) followed by 12-O-tetra-
decanoylphorbol-13 acetate (TPA) twice per week. After
a latency period of 7–11 weeks, all Cyld/ mice devel-
oped tumors, whereas only 50% of Cyld+/+ mice devel-666 Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc.oped papillomas after 11–16 weeks (Figure 1C and
Figure 2A). Induced Cyld/ mice also developed 7-fold
more and significantly larger papillomas than control litter-
mates (Figures 2B and 2C). Interestingly, tumor frequency
and growth of tumors in Cyld+/ mice was intermediate
between that of Cyld+/+ and Cyld/ (Figure 1C and Fig-
ures 2A–2C), indicating thatCyld gene dosage plays a crit-
ical role in DMBA/TPA-induced tumor development. We
analyzed all tumors of both groups of mice histologically
and observed a hyperplastic squamous epithelium and
no signs of malignancy in both Cyld/ as well as Cyld+/+
tumors (Figure 1D). Immunostaining of tumor sections re-
vealed that papillomas from control littermates expressed
high levels of Cyld, whereas Cyld was absent in Cyld/
tumors (Figure 1E).
The loss of Cyld leads to increased susceptibility to
chemically induced skin tumor formation, confirming that
Cyld functions as a tumor suppressor in skin. To determine
whether Cyld deficiency affects DMBA-induced tumor ini-
tiation or TPA-induced tumor promotion, we treated con-
trol and Cyld/ mice repeatedly with DMBA alone. This
treatment predominantly induces squamous cell carcino-
mas (Quintanilla et al., 1986) and gave rise to tumors with
similar size and number in all Cyld/ and Cyld+/+ mice
(Figures 2D–2F). This finding strongly suggests that Cyld
is required to suppress TPA-induced tumor promotion
but not DMBA-induced tumor initiation.
Cyld Regulates Proliferation and Cyclin D1
Expression in a NF-kB-Dependent Manner
The increased tumor formation in DMBA/TPA-treated
Cyld/ mice could be due to increased keratinocyte sur-
vival and/or proliferation. To determine the extent of apo-
ptosis inCyld+/+ andCyld/ tumors, we performed TUNEL
staining and immunostaining of cleaved caspase-3. These
experiments revealed that 1.0% and 1.1% of the keratino-
cytes were apoptotic in Cyld+/+ and Cyld/ tumor sec-
tions, respectively, and thus indicated that loss of Cyld
does not grossly affect tumor cell survival. To examine
cell proliferation, we compared BrdU incorporation and
Ki67 and cyclin D1 expression between Cyld/ and
Cyld+/+ tumors. Cyld/ tumors displayed a significant in-
crease in Ki67- and cyclin D1-positive cells in the basal
cell layers (Figure 3A and Figure S2). Moreover, Cyld/
tumors contained large numbers of proliferating cells
above the basal cell layer, which were never observed in
Cyld+/+ tumors (Figure 3A). These data suggest that TPA
increases tumor promotion in Cyld/ mice by enhancing
tumor cell proliferation. Therefore, we tested whether
treatment with TPA alone was sufficient to induce skin tu-
mors in Cyld/ mice. The application of a single dose of
TPA was already sufficient to induce epidermal hyperpla-
sia and to dramatically increase keratinocyte proliferation
on the back skin of Cyld/mice (Figure 3B). However, we
never observed the formation of skin tumors in Cyld/
mice, even after a prolonged TPA treatment for 20 weeks.
Altogether, these findings indicate that loss of Cyld leads
to increased TPA-induced tumor cell proliferation and,
Figure 1. Analysis of the Role of Cyld in Papilloma Formation
(A) Mouse embryonic fibroblast (MEF), skin, and brain protein extracts from Cyld+/+, Cyld+/, and Cyld/ mice probed with a Cyld-specific antibody.
(B) Histological analysis of Cyld expression (red staining) in skin of Cyld+/+ and Cyld/ mice.
(C) Representative examples of papilloma development in Cyld+/+, Cyld+/, and Cyld/ mice (n = 15) after 16 weeks of DMBA/TPA treatment.
(D) Hematoxylin-and-eosin staining of papillomas of Cyld+/+ and Cyld/ mice after 16 weeks of DMBA/TPA treatment.
(E) Cyld immunostaining (brown) of papilloma from a Cyld+/+ and Cyld/ mouse.together with additional mutations, to the formation of skin
tumors in Cyld/ mice.
We then examined whether the TPA-induced prolifera-
tion and cyclin D1 expression is also significantly in-
creased in isolated primary Cyld/ keratinocytes. The
basal proliferation rate and cyclin D1 expression level
did not differ significantly between Cyld/ and Cyld+/+
keratinocytes (Figures 3C and 3D). However, TPA treat-
ment significantly stimulated the proliferation of Cyld/,
but not Cyld+/+, keratinocytes after 48 hr (Figure 3C) and
induced a strong and progressive increase of cyclin D1
expression in Cyld/ keratinocytes, while cyclin D1 levels
in Cyld+/+ keratinocytes decreased 12 hr after TPA treat-
ment (Figure 3D).
Cylindromas develop in the face, neck, and scalp region
(van Balkom and Hennekam, 1994), and therefore UV light
is considered, at least in part, to trigger tumor growth. In-
deed, when we treated primary keratinocytes with a single
dose of UV-B, the proliferation rate as well as cyclin D1 ex-
pression increased significantly in Cyld/ keratinocytes
(Figure S3 and data not shown). In contrast to TPA or
UV-B treatment, TNF-a inhibited proliferation of bothCyld+/+ andCyld/ keratinocytes and failed to upregulate
cyclin D1 expression in Cyld/ keratinocytes (Figure 3C
and data not shown). Based on these findings, we con-
clude that TPA or UV-B light, but not TNF-a, induces cyclin
D1 expression and cell proliferation in keratinocytes and
that this response is negatively regulated by Cyld.
Cyclin D1 expression can be induced through the acti-
vation of various signaling proteins, including protein ki-
nase B (PKB/Akt), mitogen-activated protein kinase (p38
MAPK), c-Jun NH2-terminal kinase (JNK), and NF-kB
(Liang and Slingerland, 2003; Wilkinson and Millar, 2000;
Guttridge et al., 1999; Hinz and Strauss, 1999). To test
whether TPA treatment induced phosphorylation of JNK,
p38 MAPK, and Akt, we isolated primary keratinocytes
and monitored the activity of these signaling molecules
with specific phosphoantibodies. The phosphorylation of
JNK, p38 MAPK, and Akt was comparable in serum-
starved Cyld+/+ and Cyld/ keratinocytes and could be
induced by TPA in Cyld/ keratinocytes to an extent sim-
ilar to in Cyld+/+ keratinocytes (Figure S4), indicating that
these signaling proteins are unlikely to play a major role
in the upregulation of cyclin D1.Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc. 667
Figure 2. Tumor Development in Cyld/ Mice
(A–C) Tumor incidence (A), average number of tumors per mouse (B), and tumor growth (C) are significantly different between Cyld+/+ and Cyld/
mice (n = 15; p < 0.01).
(D–F) Tumor growth after DMBA treatment alone for 21 weeks is not significantly different between Cyld+/+ and Cyld/ mice (n = 10).The cyclin D1 promoter contains specific NF-kB binding
sites and robustly responds to activated NF-kB proteins in
several cell lines (Joyce et al., 2001). To examine whether
Cyld increases cyclin D1 expression in keratinocytes
through activation of NF-kB, we compared the activity of
wild-type and NF-kB binding-deficient cyclin D1 (Mut-
CD1) promoter-driven luciferase constructs in Cyld+/+
and Cyld/ keratinocytes. TPA or UV-B treatment in-
creased cyclin D1 promoter activity significantly more in
Cyld/ keratinocytes than in Cyld+/+ keratinocytes
(Figure 3E and Figure S5). The increased cyclin D1 activa-
tion inCyld/ keratinocytes was normalized upon reintro-
duction of the Cyld protein (Figure 3E). Importantly, TPA or
UV-B failed to activate the Mut-CD1 promoter in Cyld+/+
as well asCyld/ keratinocytes (Figure 3E and Figure S5),
indicating that Cyld modulates TPA- or UV-B-mediated
cyclin D1 promoter activation in an NF-kB-dependent
manner. TNF-a treatment failed to activate the cyclin D1
promoter in Cyld+/+ as well as Cyld/ keratinocytes (Fig-
ure 3E), consistent with the inability of TNF-a to stimulate
keratinocyte proliferation (Figure 3C). Based on these
data, we conclude that TPA and UV light induce the acti-
vation of the cyclin D1 promoter through NF-kB signals
that are antagonized by Cyld.
TPA and UV Light Trigger the Activation of Bcl-3/p50
and Bcl-3/p52 in Cyld/ Keratinocytes
The mammalian NF-kB family of transcription factors con-
sists of five members, p65/RelA, c-Rel, RelB, NF-kB1/p50,668 Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc.and NF-kB2/p52, which bind to the NF-kB DNA binding
sites as homo- or heterodimers (Ghosh and Karin, 2002;
Israel, 2000). Cyld has been implicated in the inhibition of
p65/p50 NF-kB through deubiquitination of TRAF2 and
subsequent stabilization of IkB-a (Trompouki et al., 2003;
Brummelkamp et al., 2003; Kovalenko et al., 2003). Hence,
Cyld/ keratinocytes should exhibit increased p65/p50
activity. To test this hypothesis, we treated keratinocytes
with TNF-a and monitored both the IkB-a levels and the
activity of the p65/p50 NF-kB-responsive 3XkB luciferase
reporter (3XkB) construct (Figure 4A). These experiments
showed that TNF-a decreased IkB-a levels more rapidly
in Cyld/ than in Cyld+/+ keratinocytes (Figure 4A) and
led to a significantly higher activation of the 3XkB luciferase
reporter (3XkB) construct in primaryCyld/ keratinocytes
compared to Cyld+/+ keratinocytes (Figure 4B). Moreover,
transfection of p65 alone or in combination with p50 in-
creased the 3XkB luciferase reporter activity to a similar
extent in Cyld+/+ and Cyld/ keratinocytes (Figure 4C),
confirming that Cyld negatively regulates p65/p50 NF-kB
activity upstream of the IkB/NF-kB complex. Surprisingly,
however, TPA treatment failed to induce IKK-mediated
phosphorylation of IkB-a and phosphorylation-induced
degradation of IkB-a in Cyld+/+ as well as in Cyld/ kera-
tinocytes (Figures 4D and 4E and Figure S6). These results
indicate that TPA triggers activation of NF-kB—unlike
TNF-a—in an IkB-a-independent manner in keratinocytes.
To address which NF-kB family member (or members)
regulates (or regulate) cyclin D1 promoter activity in
Figure 3. Cell Proliferation in the Absence of Cyld
(A) Ki67 (brown) staining in Cyld+/+ and Cyld/ tumors after application of DMBA/TPA.
(B) Cyclin D1 staining (brown) in skin 72 hr after a single application of TPA.
(C) Proliferation assay with isolated primary epidermal keratinocytes in the absence or presence of TNF-a (25 ng/ml) or TPA (100 nM). The proliferation
rate after 48 hr is significantly higher in Cyld/ compared to Cyld+/+ in the presence of TPA (n = 4; p < 0.05).
(D) Analysis of the expression levels of cyclin D1 after treatment with 100 nM TPA as indicated in Cyld+/+ and Cyld/ keratinocytes.
(E) Activation of the64 to +10 cyclin D1 promoter luciferase reporter construct with (CD1) or without (Mut-CD1) the NF-kB site inCyld+/+ andCyld/
keratinocytes in the absence or presence of TPA (100 nM; 2 hr) or TNF-a (25 ng/ml; 2 hr). The cyclin D1 activity is significantly higher in TPA-treated
Cyld/ keratinocytes compared to Cyld+/+ keratinocytes (n = 6; p < 0.05).a Cyld-dependent manner, we transiently transfected
Cyld+/+ and Cyld/ keratinocytes with the cyclin D1 pro-
moter luciferase construct and expression vectors encod-
ing p65, p50, p52, and Bcl-3 proteins alone or in combina-
tion. The proteins p50 and p52 are the final products of the
proteasome-mediated processing of two larger precur-
sors, p100 and p105, respectively, which lack transactiva-
tion domains (Ghosh and Karin, 2002; Israel, 2000). There-
fore, p50 and p52 depend on the association with the
noninhibitory IkB family member Bcl-3 (Watanabe et al.,
1997; Fujita et al., 1993; Westerheide et al., 2001; Rocha
et al., 2003). Expression of the NF-kB subunits p50, p52,
p65, or p65 and p50 together significantly increased cyclin
D1 promoter activity in neither Cyld+/+ nor Cyld/ kerati-
nocytes (Figure 4F). Similarly, addition of Bcl-3 alone failed
to increase cyclin D1 inCyld+/+ andCyld/ keratinocytes.
However, Bcl-3 in combination with p50 or p52 strongly
activated the cyclin D1 promoter. This effect was signifi-
cantly more pronounced in Cyld/ keratinocytes than inCyld+/+ cells (Figure 4F). Importantly, the increased cyclin
D1 promoter activity in Cyld/ keratinocytes was normal-
ized after re-expression of Cyld and completely abolished
in the absence of a functional NF-kB binding site (Fig-
ure 4G). Based on these data, we conclude that loss of
Cyld in keratinocytes does not promote the activity of the
p65/p50 NF-kB but rather promotes the synergistic activa-
tion of p50/Bcl-3 or p52/Bcl-3, leading to increased ex-
pression of NF-kB-dependent genes, including cyclin D1.
Cyld Regulates Nuclear Accumulation of Bcl-3
in Keratinocytes
To unravel the mechanism underlying the inhibitory activ-
ity of Cyld on TPA-mediated p50/Bcl-3 or p52/Bcl-3, we
first determined the subcellular localization of Cyld and
Bcl-3 in keratinocytes. Expression of an EGFP-tagged
Cyld in Cyld/ keratinocytes revealed a cytoplasmic dis-
tribution (Figure 5A). Within 30 min after TPA or UV-B treat-
ment, Cyld translocated to and accumulated at theCell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc. 669
Figure 4. NF-kB-Dependent 3XkB Lucif-
erase Reporter Activity
(A) IkB-a expression level after stimulation with
TNF-a in Cyld+/+ and Cyld/ keratinocytes.
(B) Activation of 3XkB luciferase reporter con-
struct in Cyld+/+ and Cyld/ keratinocytes in
the absence or presence of TNF-a (25 ng/ml;
2 hr) and expression vectors encoding the HA
tag or the HA-tagged Cyld.
(C) 3XkB luciferase reporter activity in Cyld+/+
and Cyld/ keratinocytes transfected with ex-
pression plasmids encoding p50 or p65 alone
or in combination as indicated.
(D) Phospho-IkB-a (pIkB-a) expression level af-
ter stimulation with TPA or TNF-a inCyld+/+ and
Cyld/ keratinocytes.
(E) IkB-a expression level after stimulation with
TPA in Cyld+/+ and Cyld/ keratinocytes.
(F) Cyclin D1 promoter activity is significantly
increased in Cyld/ keratinocytes upon ex-
pression of p50/Bcl-3 or p52/Bcl-3 (n = 5;
p < 0.05).
(G) Cyld/ keratinocytes were cotransfected
with the 64 to +10 cyclin D1 promoter lucifer-
ase construct with (CD1) or without (Mut-CD1)
the kB site and expression vectors encoding
the HA tag or the HA-tagged Cyld alone or in
combination, plus p50 or p52 and Bcl-3, as
indicated.perinuclear region, where it colocalized with Bcl-3 (Figures
5A and 5B and Figure S8). The perinuclear accumulation
of Cyld was not due to changes in cell shape because
F-actin staining of TPA-treated keratinocytes revealed
normal cell spreading (Figure 5A).
The colocalization of Cyld and Bcl-3 in the perinuclear
region of TPA- or UV-B-treated keratinocytes suggested
that Cyld may associate with Bcl-3 and regulate its activ-
ity. Coimmunoprecipitation experiments in primary kerati-
nocytes revealed that TPA facilitated the association of
endogenous Cyld with endogenous Bcl-3 already 15 min
after TPA treatment (Figure 5C). To examine whether the
interaction between Cyld and Bcl-3 is achieved through
a direct or an indirect interaction, we performed yeast
two-hybrid assays. These assays revealed that full length
Bcl-3 indeed interacted with Cyld and that the binding site
for Bcl-3 on Cyld corresponded to the C-terminal part of
the protein (Figures 5D and S7). The consequences of
this interaction for the subcellular localization of Bcl-3
were further tested in TPA- as well as UV-B-treated kera-
tinocytes. Either treatment increased nuclear transloca-
tion of Bcl-3 significantly more in Cyld/ than in Cyld+/+
keratinocytes (Figures 5E and 5G and Figures S8),670 Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc.while the level of cytoplasmic Bcl-3 decreased concomi-
tantly in Cyld/ but not Cyld+/+ keratinocytes (Figure 5F).
Importantly, nuclear accumulation of Bcl-3 was also
significantly increased in DMBA/TPA-induced Cyld/
tumors when compared with tumors from control litter-
mates (Figure 5H). Moreover, immunostaining revealed
increased nuclear staining of Bcl-3 in tumor cells from hu-
man cylindromas (Figure 5H), whereas in both normal
human and murine epidermal keratinocytes, Bcl-3 was lo-
calized in the cytoplasm (Figures 5H and 5I). These find-
ings indicate that Bcl-3 is regulated similarly in human cy-
lindromas, as well as in DMBA/TPA-induced murine skin
tumors.
The nuclear accumulation of Bcl-3 and the increased
expression of cyclin D1 in tumors and TPA-treated kerati-
nocytes from Cyld/ mice suggest that Bcl-3 becomes
directly bound to the NF-kB binding site of the cyclin D1
promoter to switch on p50 and p52 activity in Cyld/
cells. To test this hypothesis, we performed chromatin im-
munoprecipitation (ChIP) experiments with anti-Bcl-3 an-
tibodies and semiquantitative PCR amplification of immu-
noprecipitated chromatin fragments flanking the NF-kB
binding site in the cyclin D1 gene. The ChIP experiments
Figure 5. Effects of TPA on the Subcellular Localization of Cyld and Bcl-3
(A) Confocal plane of untreated and TPA-treated (30 min)Cyld/ keratinocytes stably transfected with EGFP-Cyld (green) and stained for F-actin (red)
and DAPI (blue).
(B) Cyld/ keratinocytes stably expressing EGFP-Cyld (green) were stimulated with TPA for 30 min and stained for Bcl-3 (red) and DAPI (blue).
(C) Cyld+/+ keratinocytes were stimulated with TPA for the indicated time periods, lysed, immunoprecipitated with an anti-Bcl-3 antibody, and then
probed with an anti-Cyld antibody (upper panel). The blot was reprobed with an anti-Bcl-3 antibody (middle panel). Lysate (lower panel) shows equal
amount of Bcl-3 used for immunoprecipitation.
(D) Specific interaction of Cyld and Bcl-3 in yeast. Growth on selective medium of yeast cotransfected with AD (empty vector) and Cyld (470–957) BD
(upper panel) or Bcl-3 AD and Cyld (470–957) BD (middle panel). Specific b-galactosidase activity for Cyld (470–957) BD and Bcl-3 AD colonies is
shown in the bottom panel.
(E) Cyld+/+ and Cyld/ keratinocytes were treated with TPA, and nuclear extracts were prepared and immunoblotted with antibodies against p52,
p65, Bcl-3, and laminA/C.
(F) Cyld+/+ and Cyld/ keratinocytes were treated with TPA, and the cytoplasmic fraction was purified and immunoblotted with antibodies against
p52, p65, Bcl-3, and tubulin.
(G) Confocal plane of untreated and TPA-treated (30 min) Cyld+/+ and Cyld/ keratinocytes stained for Bcl-3 (red) and DAPI (blue).
(H) Bcl-3 (brown) staining in Cyld+/+ and Cyld/ tumors and human cylindromas. The arrows (insert) indicate nuclear localization of Bcl-3.
(I) Percentage of cells with nuclear staining of Bcl-3 in Cyld+/+ and Cyld/ interfollicular epidermis or DMBA/TPA induced tumors versus human
interfollicular epidermis and cylindromas.
(J) Recruitment of Bcl-3, p65, p52, and p50 to the cyclin D1 promoter by ChIP using untreated or TPA-stimulated (30 min) primary keratinocytes.
IP:Bcl-3, IP:p65, IP:p52, and IP:p50, immunoprecipitation (IP) using polyclonal antibodies as indicated; IP:IgG, IP using preimmune serum; input,
10% of the cell lysate used for the IP is shown.clearly demonstrated that no DNA bound Bcl-3 was de-
tected in resting Cyld+/+ and Cyld/ keratinocytes. TPA
treatment, however, resulted in Bcl-3 binding to endoge-
nous cyclin D1 sequences in Cyld/ keratinocytes, but
not in Cyld+/+ keratinocytes (Figure 5J). Interestingly,
TPA also triggered the recruitment of p50 or p52, but not
p65, to the cyclin D1 promoter in Cyld/ keratinocytes
(Figure 5J). These data supports a model in which TPA
or UV-B treatment leads to the translocation of Cyld to
the perinuclear region, where Cyld binds Bcl-3 and inhibits
its nuclear accumulation. In the absence of Cyld, however,Bcl-3 accumulates in the nucleus and forms a complex
with p50 or p52 that is recruited to the NF-kB site in the
cyclin D1 promoter.
Depletion of Bcl-3 in Cyld/ Keratinocytes
Reduces TPA-Induced cyclin D1 Promoter
Activity and Proliferation
If the increased nuclear accumulation of Bcl-3 and the el-
evated binding to the NF-kB binding site of the cyclin D1
promoter are indeed directly responsible for the enhanced
cyclin D1 expression and proliferation of Cyld/Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc. 671
Figure 6. siRNA-Induced Knockdown of Bcl-3 in Keratinocytes
(A) Confocal plane of Bcl-3 (red) and DAPI (blue) in control- or Bcl-3 siRNA-transfected Cyld/ keratinocytes.
(B) Western blot analysis of Bcl-3, p50, p52, and p65 proteins inCyld/ keratinocytes before or after transfection with Bcl-3 siRNA. Numbers indicate
the ratio of Bcl-3 protein in nontransfected cells versus siRNA-transfected cells.
(C) Activation of the cyclin D1 promoter luciferase reporter in Cyld+/+ and Cyld/ keratinocytes cotransfected with control or Bcl-3-specific siRNA in
the absence or presence of TPA (100 nM; 2 hr). Transfection of Bcl-3 siRNA significantly reduced TPA-induced cyclin D1 activity when compared to
control siRNA (n = 4; p < 0.05).
(D) Cell proliferation assay ofCyld+/+ and Cyld/ keratinocytes cotransfected with control or Bcl-3-specific siRNA in the absence or presence of TPA
(100 nM). The proliferation rate after 48 hr is significantly reduced upon Bcl-3 siRNA transfection (n = 6; p < 0.05).keratinocytes, depletion of Bcl-3 should reverse the phe-
notype. We therefore used small interfering RNA (siRNA)
to deplete Bcl-3 expression in Cyld+/+ and Cyld/ kerati-
nocytes (Figures 6A and 6B), which had no apparent im-
pact on the levels of NF-kB p50, p52, and p65 (Figures
6B). Depletion of Bcl-3 significantly reduced TPA-induced
cyclin D1 promoter activation in both Cyld/ and Cyld+/+
keratinocytes. Treatment of keratinocytes with control
siRNA unrelated to any known genes did not affect cyclin
D1 activity (Figure 6C). Similarly, depletion of Bcl-3 also
reversed the increased proliferation rate of Cyld/ kerati-
nocytes, while treatment with control siRNA had no effect
(Figure 6D). These findings indicate that Bcl-3 is required
for the inhibitory effect of Cyld on TPA- and UV-induced
cyclin D1 activation and proliferation.672 Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc.Cyld-Mediated Deubiquitination of Bcl-3 Prevents
Accumulation of Bcl-3 in the Nucleus
To test whether the retention of Bcl-3 is dependent on the
deubiquitinating activity of Cyld, we immunoprecipitated
endogenous Bcl-3 in untreated and TPA-treated Cyld+/+
and Cyld/ keratinocytes and subsequently determined
the modification of Bcl-3 with ubiquitin. The polyubiquiti-
nation of Bcl-3 in untreated Cyld+/+ and Cyld/ keratino-
cytes was weak and similar between the two cell types.
While TPA stimulation failed to increase the polyubiquiti-
nation of Bcl-3 in Cyld+/+ keratinocytes, it caused signi-
ficant polyubiquitination of Bcl-3 in Cyld/ keratinocytes
30 min after TPA addition, which further increased within
60 min (Figure 7A). In order to determine the type of poly-
ubiquitin chains that Cyld removes from Bcl-3 in vivo, we
Figure 7. Deubiquitination of Bcl-3 by
Cyld
(A) Endogenous ubiquitination of Bcl-3 using
Cyld+/+ and Cyld/ keratinocytes in the pres-
ence or absence of TPA. The top panel shows
immunoprecipitation with antibodies directed
against Bcl-3 or control antibodies (preimmune
serum; IgG). Immunoprecipitates were re-
solved on an SDS gel and probed with anti-
ubiquitin antibodies. The middle panel shows
that equal amounts of Bcl-3 were used for im-
munoprecipitation. The lower panel shows
cell lysate probed with anti-tubulin antibody.
(B) HeLa cells were transfected with mutant
His-tagged ubiquitin cDNAs, Flag-tagged Bcl-
3, and full-length wild-type Cyld (FL-Cyld).
Bcl-3 was immunoprecipitated with an anti-
Flag (M2) antibody and then immunoblotted
with antisera against ubiquitin, stripped, and
reprobed with an antibody against Flag.
(C) Ubiquitination of Bcl-3 was carried out as in
(B) in the presence of the ubiquitin mutants and
with either full-length wild-type Cyld (FL-Cyld)
or enzymatically inactive Cyld (C/S-Cyld) as
indicated.
(D) Confocal plane of TPA-stimulated (30 min)
Cyld/ keratinocytes transduced with FL-
Cyld (green) or C/S-Cyld (green) and immuno-
stained for Bcl-3 (red). Inserts show Bcl-3 local-
ization only.
(E) Activation of the 64 to +10 cyclin D1 pro-
moter luciferase reporter construct with the
kB site in Cyld/ (CD1), FL-Cyld, or C/S mu-
tant stably transfected keratinocytes in the ab-
sence or presence of TPA (100 nM, 2 hr). The
cyclin D1 activity in TPA-treated FL-Cyld kera-
tinocytes compared to C/S mutant is signifi-
cantly different (n = 5; p < 0.05).performed ubiquitination assays using specific point mu-
tants of His-tagged ubiquitin in which either K48 or K63
is replaced by an arginine (UbK48R and UbK63R). While
Cyld removed UbK48R from Bcl-3 very efficiently, Cyld
was unable to remove UbK63R (Figure 7B). Altogether,
these findings indicate that Cyld catalyzes the disassem-
bly of K63-linked rather than K48-linked polyubiquitin
chains on Bcl-3 in vivo.
To further test the importance of the deubiquitinase
activity of Cyld for nuclear accumulation and function of
Bcl-3, we rescued Cyld/ keratinocytes with full-length
Cyld (FL-Cyld) and a Cyld cDNA that carries a point muta-
tion in the cysteine box of the deubiquitinase domain
(C/S-Cyld; Brummelkamp et al., 2003). Expression of the
C/S-Cyld in Cyld/ keratinocytes was indeed unable to
remove K63-linked ubiquitin chains from Bcl-3
(Figure 7C). To test whether C/S-Cyld is able to reverse
the cyclin D1 hyperactivation and proliferation of Cyld/keratinocytes, we expressed the catalytically inactive mu-
tant or the wild-type form of full-length Cyld in Cyld/
keratinocytes. As expected, wild-type Cyld efficiently in-
hibited TPA- or UV-B-induced nuclear accumulation of
Bcl-3, while the catalytically inactive mutant of Cyld
was unable to prevent nuclear accumulation of Bcl-3
(Figure 7D) and activation of the cyclin D1 promoter
(Figure 7E). Based on these data, we conclude that Cyld
binds to and removes lysine 63-linked ubiquitin chains
from Bcl-3 in TPA- or UV-B-treated keratinocytes and
that deubiquitination prevents Bcl-3 accumulation in the
nucleus and activation of the cyclin D1 promoter (Figure 8).
DISCUSSION
Mutations in the tumor suppressor gene CYLD cause be-
nign tumors called cylindromas that are believed toCell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc. 673
develop from hair-follicle keratinocytes (Bignell et al.,
2000). In the search for the tumor suppressor function of
CYLD, several laboratories reported that CYLD can inhibit
the activation of the classical NF-kB p65/p50 transcription
factor (Trompouki et al., 2003; Brummelkamp et al., 2003;
Kovalenko et al., 2003; Regamey et al., 2003). While hy-
peractivation of NF-kB p65/p50 promotes cell survival
and/or cell proliferation in most cell types (Karin et al.,
2002), keratinocytes respond with growth arrest and
terminal differentiation (Seitz et al., 1998), pointing to the
possibility that additional signaling pathways may be af-
fected in Cyld-deficient tumor cells. In the present paper,
we tested this hypothesis by analyzing skin tumor forma-
tion in mice lacking Cyld.
Cyld-deficient mice developed and aged normally de-
spite the ubiquitous expression pattern of Cyld. When
we induced tumors with DMBA and TPA in Cyld-deficient
mice, we found that they suffered from a significantly
higher tumor incidence and developed significantly larger
and more tumors than their littermate controls. The in-
creased tumor development in Cyld-deficient mice was
due to a dramatically elevated tumor cell proliferation,
while tumor cell survival was not significantly altered. In
search of a mechanistic explanation for the dysregulated
proliferation rate in Cyld-deficient tumors, we identified
several steps of a signaling pathway in which Cyld under-
takes the principal task of controlling the nuclear translo-
cation of Bcl-3, which in turn alters the transcriptional
properties of the NF-kB p50 and p52 homodimers.
Growth-promoting signals such as TPA or UV light trigger
the translocation of Cyld and Bcl-3 from the cytoplasm to
the perinuclear region. Following this translocation, Cyld
removes K63-linked polyubiquitin chains from Bcl-3,
which prevents Bcl-3 from translocating into the nucleus.
In support of these findings, we observed that loss of Cyld
Figure 8. Model of How Cyld Regulates TNF-a- or TPA/UV-
Induced NF-kB Signaling in Keratinocytes674 Cell 125, 665–677, May 19, 2006 ª2006 Elsevier Inc.or the expression of a catalytically inactive Cyld mutant
failed to deubiquitinate the perinuclear Bcl-3, which in
turn facilitated the nuclear accumulation of Bcl-3. Nuclear
Bcl-3 associated with p50 and p52 at NF-kB binding sites
and activated transcription of NF-kB target genes such as
cyclin D1. Importantly, the same signaling pathway de-
scribed here for mouse epidermal keratinocytes also oper-
ates in human cylindromas, which are believed to develop
from hair follicles. Immunostaining of tumor sections from
cylindroma patients revealed that the majority of tumor
cells contained Bcl-3 in the nucleus, while epidermal or
hair-follicle keratinocytes of normal human skin retained
Bcl-3 in the cytoplasm, strongly suggesting that CYLD
also controls Bcl-3 translocation into the nucleus of hair-
follicle keratinocytes.
Our findings show that the cytoplasmic Bcl-3 is inactive
and requires lysine 63 polyubiquitination in order to trans-
locate into the nucleus. The polyubiquitin modification of
Bcl-3 could facilitate the interaction with nuclear transport
receptors (called importins) and mediate the transport
through the nuclear core complex, as shown for the mono-
ubiquitinated E2 conjugating enzyme UbcM2 (Plafker
et al., 2004). It is also conceivable, however, that the poly-
ubiquitin chains of Bcl-3 enable binding to nuclear pro-
teins with the consequence that such interactions target
Bcl-3 to a specific nuclear compartment. Nuclear Bcl-3
was shown to associate with p50 and p52 in a large num-
ber of different tumor cell lines and to promote cell prolif-
eration and oncogenesis through the activation of the cy-
clin D1 gene (Cogswell et al., 2000; Thornburg et al., 2003;
Budunova et al., 1999). In light of our current findings, it will
be important to determine whether the increased nuclear
Bcl-3 levels in these tumor cell lines are (like in cylindro-
mas and epidermal tumors) also caused by absent or de-
creased Cyld expression.
Since most tumors in our mouse model develop from
epidermal keratinocytes rather than from hair-follicle ker-
atinocytes, we began to determine the CYLD levels in hu-
man skin tumors such as basal cell carcinomas (BCC) and
squamous cell carcinomas (SCC) that also develop from
epidermal keratinocytes. Interestingly, we observed re-
duced or absent expression of CYLD in more than ten sam-
ples of BCC and SCC, respectively (R.M., unpublished
data). This strongly suggests that CYLD plays a general
role as a tumor suppressor, which is in agreement with its
ubiquitous expression pattern and with a recent observa-
tion showing that CYLD levels are downregulated in several
other tumors such as kidney, liver, and uterine cervix (Stro-
bel et al., 2002; Hashimoto et al., 2004; Hirai et al., 2004).
Although TNF-a-induced signaling via TRAF2-depen-
dent p65/p50 activation is enhanced in Cyld-deficient
keratinocytes, the significance of this pathway for the de-
velopment of tumors is not clear. On one hand, overex-
pression of NF-kB p65/p50 stimulated neither the basal
nor the TPA-induced proliferation rate of Cyld-deficient
keratinocytes, suggesting that the classical NF-kB signal-
ing pathway is not contributing to the exacerbation of
tumor cell proliferation in Cyld-deficient tumors. On the
other hand, we found no compelling evidence for an en-
hanced survival of tumor cells in Cyld-deficient mice. It
is possible, however, that NF-kB dependent p65/p50 sig-
naling becomes crucial when cylindroma tumors reach
a certain size and erode, leading to bacterial superinfec-
tion. In such situations, pathogens and cytokines may ac-
tivate NF-kB p65/p50 signaling through Toll-like receptors
and cytokine receptors, which are expressed on keratino-
cytes (Mempel et al., 2003; Kollisch et al., 2005), and may
then promote survival of tumor cells and contribute to the
growth of Cyld-deficient tumors. If so, the mode of stimu-
lation may dictate whether Cyld controls inflammation
through TRAF signaling and p65/p50 activation (Figure 8)
or tumor growth through Bcl-3 activation, NF-kB p50 and/
or p52 binding, and, finally, activation of NF-kB-depen-
dent gene transcription.
EXPERIMENTAL PROCEDURES
Generation of Cyld/ Mice and Genotyping
Cyld/ mice were generated with a targeting construct in which the
ATG-containing exon 4 of the Cyld gene was disrupted with a lacZ re-
porter and a neomycin gene. The targeting vector was electroporated
into R1 embryonic stem (ES) cells (passage 13), and two independently
targeted ES cell clones were injected into C57Bl/6 blastocysts to
generate germline chimeras. The chimeric founders were crossed to
C57Bl/6 females to establish heterozygous Cyld+/ and subsequently
homozygous Cyld/mice. Fifth-generation backcrosses into C57Bl/6
were used for the chemically induced tumor experiments.
Sections of mouse tumor tissues or cylindromas from three patients
were fixed with 3% PFA, paraffin embedded, and stained with an affin-
ity-purified rabbit anti-mouse Cyld antiserum or a rabbit anti-Bcl-3
antiserum.
Carcinogenesis Protocols
For two-stage chemical carcinogenesis, cohorts of 8-week-old sex-
matched Cyld+/+, Cyld+/, and Cyld/ littermates backcrossed five
times to C57Bl/6 were treated for 1 week with DMBA (25 mg in 200 ml
acetone) and then for 16 weeks with TPA (200 ml of 104 M solution
in acetone). For complete carcinogenesis, mice were treated biweekly
with 5 mg DMBA alone in 200 ml acetone for 21 weeks. Tumors and or-
gans were snap frozen in liquid nitrogen, fixed in formalin, and stained
with hematoxylin and eosin or antisera against Cyld (generated by im-
munizing rabbits with a bacterially expressed GST-fusion protein with
the N-terminal 323 amino acids of mouse Cyld), BrdU (DAKO), Ki-67
(Novocastra), or cyclin D1 (Santa Cruz). Secondary antibodies were
purchased from Jackson Laboratories.
Cell Proliferation and Apoptosis in Skin
Cohorts of Cyld+/+ and Cyld/ littermates were treated with a single
application of TPA alone, injected intraperitoneally with BrdU (100
mg/kg; Sigma) 48 hr later, and then killed 3 hr later. Cell proliferation
was determined in skin sections using antibodies against BrdU
(DAKO), Ki67 antigen (Novocastra), or cyclin D1 (Santa Cruz). Apopto-
sis was determined by immunostaining for cleaved caspase-3 (Cell
Signaling) or visualizing TUNEL (TdT-mediated dUTP nick end labeling)
positive cells. The percentage of signal-positive keratinocytes in the
basal layer of interfollicular epidermis was calculated from ten different
fields of at least five different tumors.
Primary Keratinocyte Culture, Transfection,
and Reporter Assays
Primary keratinocytes were isolated from back skin of 8-week-old
mice and cultured as described (Romero et al., 1999). The p50, p52,p65, and Bcl-3 expression constructs and the 64 to +10 cyclin D1
promoter luciferase reporter construct with (pCD1) and without (Mut-
CD1) the NF-kB binding were used for the luciferase activation assay.
HA-tagged Cyld was PCR amplified and cloned into pCS2 vector. Cell
transfection assays were carried out in six-well plates at 80% conflu-
ence with Polyfectamine (QIAGEN) according to the manufacturer’s
instructions. All cell transfection assays were repeated between four
and six times (as indicated) and were always done in triplicate. To as-
say for transfection efficiency, transfections were done with a constant
amount of a Renilla expression plasmid. Luciferase and Renilla activi-
ties were assayed 24 hr after transfection according to the manufac-
turer’s instructions (Promega). TPA or TNF-a (both purchased from
Sigma) stimulation was done for 2 hr. Stable expression of Cyld was
achieved by retro- or lentiviral infection (Pfeifer et al., 2000). siRNAs
(control and Bcl-3) were purchased from Santa Cruz and used accord-
ing to the manufacturer’s instructions. siRNA transfections were made
with HiPerFect transfection reagent (QIAGEN).
Immunoblots, Immunoprecipitation, and Chromatin
Immunoprecipitation
For immunoblotting, lysates from whole cells and cytosolic and nuclear
extracts were resolved in SDS-PAGE gels, transferred to PVDF mem-
branes, and incubated with the following antibodies: anti-SAPK/JNK,
anti-phospho-p38 MAP kinase, anti-phospho-Akt, anti-phospho-
SAPK/JNK, anti-p38 MAP kinase, anti-phospho-IkB-a, and anti-Akt
(all from Cell Signaling); anti-IkB-a (c-21), anti-p65, anti-p50, anti-ubiq-
uitin, and anti-Bcl-3 (from Santa Cruz); and anti-p52 (from Abcam).
For immunoprecipitations, lysates were obtained from untreated or
TPA-treated (100 nM TPA for different time periods: 15, 30, 60, or 90 min)
primary keratinocytes. The samples were centrifuged at 10,000 3 g
for 20 min. For anti-Bcl-3 immunoprecipitation, the lysates were pre-
cleared for 30 min at 4ºC. The protein content was determined and
compensated for equal content in all supernatants. For testing protein
input, a small part of the resulting lysates was gel separated and immu-
noblotted (Bcl-3 protein input, Figure 7A), and the remaining part was
used for immunoprecipitation. Immunoblots were developed with the
ECL-plus reagent (Amersham Biosciences) according to the manufac-
turer’s instructions.
Chromatin immunoprecipitation (ChIP) was performed according to
the manufacturer’s instructions (Imgenex Corporation) using either
Bcl-3 (Santa Cruz); p50, p52, or p50 antibodies; or rabbit IgG. The ex-
tracted DNA was used for semiquantitative PCR to amplify the cyclin
D1 promoter region.
Two-Hybrid and Galactosidase Assays
Cyld and Bcl-3 cDNAs were cloned as bait and prey in pGBKT7 (BD)
and pGADT7 (AD) (Clontech), respectively. Two-hybrid interaction
analyses were done using the Matchmaker Two-Hybrid System (Clon-
tech) according to the manufacturer’s instructions. In brief, after selec-
tion of cotransformants, the interaction of fusion proteins was detected
on high-stringency plates (SD/Ade/His/Leu/Trp) and verified by
b-galactosidase filter assays.
Statistical Analysis
Values are presented as the means ± SEM, with n indicating the num-
ber of independent experiments. Statistical differences were deter-
mined using Student’s t test.
Supplemental Data
Supplemental Data include eight figures and can be found with this
article online at http://www.cell.com/cgi/content/full/125/4/665/DC1/.
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